ABSTRACT Aim: This study aimed to see whether measuring serum glutamate in children with autism spectrum disorder (ASD) could provide a biological marker that could allow early intervention.
INTRODUCTION
The term autism spectrum disorders (ASD) comprises a group of neuropsychiatric disorders characterised by impairments in social communication and repetitive behaviours relative to the developmental level (1) . During the last decade, the dramatic increase in the prevalence of ASD has caused great concern among academics and society as a whole. In America, the 2016 National Health Interview Survey, which was based on parental reports, suggested that the prevalence of ASD had increased to one in 45 children, aged 3-17 (2) .
One of the proposed theories that have tried to explore the pathophysiology of ASD is the theory of glutamate excitotoxicity (3) . Glutamate is known to be the principal excitatory neurotransmitter in the brain and it is used by about 60% of the neurons in the brain as their primary neurotransmitter (4) . It has been suggested that it plays an important role during early prenatal life in modulating important developmental processes such as neuronal migration, differentiation, growth cone motility and synaptogenesis (5) . In addition, the uptake and recycling of glutamate requires nearly two-thirds of brain energy metabolism (6) and the activity of glutamate receptors is essential in maintaining fast synaptic transmission, synaptic plasticity, learning, memory, motor coordination and pain transmission (7) .
The relationship between glutamate as a main excitatory neurotransmitter in the brain and the neurodevelopmental disorders has been discussed for many years. Research has found that the imbalance in the excitation/inhibition ratio is an important underlying mechanism in the pathophysiology of ASD. It has been reported that this imbalance is Abbreviations ASD, Autism spectrum disorder; CARS, Childhood autism rating scale.
Key notes
We studied whether serum glutamate levels could provide a biological marker for autism spectrum disorder (ASD) in children aged 3-10 years. The 30 children in the ASD group showed significantly higher mean values (5.888) than the control group (2.521) and these were not affected by taking risperidone. Our view is that higher levels of serum glutamate in children with ASD might reflect altered glutamatergic neurotransmission and aid early ASD detection. mainly due to impairment in the glutamatergic and GABergic neurotransmissions which leads to increase in the excitation in different brain regions such as the neocortex, hippocampus and amygdala with an underlying deficient GABergic inhibition. It has been suggested that this increased glutametergic excitation possibly could cause excessive stimulation of abundant glutamate receptors in the brain leading to destructive ecitotoxicity (8) .
There are a series of events in the excitotoxic cascade that may lead to neuronal destruction and these events result from excessive activation of the N-Methyl-D-Aspartate receptors. At the start of the process, glutamate increases the activity of nitric oxide synthetase leading to an increase in the level of nitric oxide. This elevation can generate high levels of peroxynitrite especially in the presence of increased levels of superoxide. Peroxynitrite is characterised as being very toxic to the mitochondria, which is considered to be the main source of cellular energy production. The excitotoxic cascade may end up causing mitochondrial death and consequently neuronal death or damage (9) .
A study was conducted on pluripotent stem cells to investigate the effect of excitoxicity on neurons. The authors reported that human embryonic-derived neurons showed excitotoxic cell death at the concentrations of glutamate that were found in the brains of human patients presenting with acquired brain damage. This proved the impact of excitotoxic level of glutamate on neuronal death (10) .
On the other hand, there have been many studies that have discussed the disruption of the blood brain barrier in ASD and the role of oxidative stress in this disruption. One study found that the oxidative stress and neuro-inflammation in the ASD brain led to an altered genetic expression associated with impairment in the blood brain barrier integrity (11) . It could be affected by oxidative stress inducers at early stages of different brain diseases (12) . Moreover, the blood brain barrier remained incompetent during early embryonic development and even during early postnatal life (13) .
So, the increase in excitatory glutamate together with the disruption of the blood brain barrier in the autistic brain may result in an increase in the serum glutamate in children presenting with ASD. This could provide a potentially detectable biomarker in this mysterious disorder. However, there are still other causes that may lead to glutamatemediated excitotoxicity, such as mercury, which need to be further investigated (14) .
In this study, we hypothesised that alterations of glutamatergic neurotransmission would result in excitotoxicity and abnormal development of the nervous system, which could be manifested as an increase in the serum glutamate. The aim of the study was to estimate the level of serum glutamate in Egyptian children presenting with ASD and compare them to healthy controls to detect the role that glutamate plays in the pathophysiology of ASD. We also wanted to explore whether serum glutamate could be a biological biomarker that could help in the early intervention and treatment of ASD.
PATIENTS AND METHODS
This case control study of Egyptian children ran from January to July 2015 and comprised patient and control groups. The ASD group consisted of 30 patients aged 3-10 years of age who presented with ASD and were selected randomly from the Autism Spectrum Disorders Outpatient Clinic at the Abou El-Reesh Hospitals, Cairo University. The control group consisted of 30 children in the same age group who did not present with any mental disorder or major medical illness and were randomly selected from the siblings of children attending the Nocturnal Enuresis Outpatient clinic in the same hospital. Patients and controls were excluded from the study if they had a diagnosis of fragile X or, any major physical handicap like motor, visual or auditory impairment. Children with major medical illness or inborn errors of metabolism, neurological disorder other than epilepsy or a positive past history of repeated head trauma were also excluded from both groups.
The patients with ASD were assessed according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. The Vineland Social Maturity Scale was applied to the two groups while the Childhood Autism Rating Scale (CARS) was applied to the ASD group to assess the degree of autism. Blood samples were collected from both groups. Informed oral and written consents were provided by the caregivers of the participants. The aim of the study was explained to them as well as how the samples would be taken and the psychometric tests that would be applied.
The Vineland Social Maturity Scale is a 117-item interview with a parent or other primary caregiver that is used to measure social competence, self-help skills and adaptive behaviour. The CARS was developed by Schopler, Reichier and Rochen. It is used to rate the patients on a scale that ranges from non-autistic to mildly autistic, moderately autistic or severely autistic. The total CARS scores range from 15 to 60.
Serum glutamate measurement
All blood samples were collected between 9 am and 12 noon from the median cubital vein with the aid of a tourniquet applied to the arm. They were stored at À80°C and the precautions undertaken included avoiding high temperatures before centrifugation of the samples to avoid hemolysis. Also, vigorous shaking of the tubes was avoided. Samples were kept in serum tubes and centrifugation was carried out within 30 minutes to allow the formation of the clot but avoid haemolysis of the red blood cells. Samples were centrifuged for about 10 minutes then the serum was separated from the blood.
The glutamate assay kit is based on glutamate dehydrogenase and is based on an enzyme-catalysed kinetic reaction. The nicotinamide adenine dinucleotide and hydrogen that are produced by the catalysed oxidation of glutamate reduce the formazon reagent. The intensity of the product colour, measured at 565 nm, is proportionate to the glutamate concentration in the sample. We measured the optical density baseline and at 30 minutes at room temperature after adding a single working reagent. The working reagent was added quickly and mixing was brief, but thorough. All reagents were stored at À20°C and we avoided a lower temperature as its effect on the kit has not been tested before.
Statistical analysis
All data were evaluated using SPSS software, version 16 (IBM Corporation, New York, NY, USA). The unpaired t-test was used to compare the numerical data in the two groups. The chi-square test was used to compare the categorical data while the Pearson correlation test was used to find correlations between the numerical data.
RESULTS
In this study, the mean age of 30 patients (24 boys) was 6.37 years compared to 7.43 years for the 30 subjects (18 boys) in the control group. According to the Vineland social maturity scale, 8 (27%) of the patients had comorbid mild mental retardation while 22 (73%) had a diagnosis of moderate to severe mental retardation. Of the 30 patients, seven had epilepsy. There were 14 patients (47%) who had been free from drugs for at least six weeks, while the other 16 patients (53%) were receiving a 1-2 mg dose of risperidone per day. A third of the ASD group (33%) was firstborn children compared to seven children (23%) from the control group. In contrast, ASD subjects were less likely to be the fourth-(7% vs 13.3%) or fifth-born child (7% vs 3%). There was no statistical significance between the two groups concerning birth order.
There was a significant difference (p = 0.0002) in the level of serum glutamate between the two groups as the patient group showed a significantly higher mean (5.888 AE 2.612) than the control group (2.521 AE 0.987). There was no significant statistical difference (p = 0.151) in the serum levels of glutamate between patients receiving 1-2 mg of risperidone (6.519 AE 2.851) and those who were free from any medication for at least six weeks (5.157 AE 2.184).
We also found that there was a higher percentage of physiological and pathological neonatal jaundice in the patient group (43%) than the control group (7%) and this was a significant statistical difference (p = 0.001). A fifth (20%) of the mothers in the control group had dental amalgam fillings during pregnancy compared to 10% of mothers in the patients' group. This was assessed to investigate the potential risk of mercury in amalgam fillings during pregnancy but no significant differences were found between the two groups. There were higher percentages of Caesarien sections in the patients' group (50%) than in the control group (13%) with significant statistical differences between the two groups (p = 0.002). We did not find a significant correlation between the serum levels of glutamate and the scores in the Vineland Social Maturity Scale (p = 0.554, r = 0.112). There were no significant correlations between the serum glutamate levels and the total CARS score (r = 0.167) or its subscales (r = À0.089), as shown in Table 1 .
DISCUSSION
This study aimed to estimate the level of serum glutamate in children presenting with ASD in order to compare it with the serum glutamate levels in healthy children. We found that there was a significant statistical difference between the two groups. This could be a step in proving the hypothesis that alterations in glutamatergic neurotransmission can increase oxidative stress. This, in turn, might lead to neuronal excitotoxicity and abnormal development of the nervous system, which can be directly involved in the pathophysiology of ASD.
The most attractive and convincing part of this hypothesis was that it was consistent with many of the theories put forward and research carried out to explore the aetiology of ASD. In fact, it explained many of these theories pointing to the glutamate excitotoxicity as the underlying central mechanism behind them. These theories include the role of oxidative stress in the pathophysiology of autism and consequently the role of antioxidants in psychopharmacology (15) , mitochondrial dysfunction as a cause of early neuronal death (16) , altered cytokine levels and the role of the immune system in the pathophysiology of ASD (17) . All of these were considered as parts of an excitotoxic cascade that starts with glutamatergic neurotransmission dysfunction and ends with neuronal death in the early developmental stages leading to appearance of ASD (18) .
Another fact that has been established is that the symptoms of autism appear before three years of age (19) . This can be related to the important study finding that reported that around the age of two years, the developing brain contained more synaptic glutamate receptors than at birth and the density declined over the next decade meaning that the very immature brain was more susceptible to excitotoxic levels (20) . Our study showed that the high serum level of glutamate in patients was consistent with two other studies (21, 22) which examined serum glutamate in children and adults presenting with ASD. Both of these showed increased serum glutamate. However, our findings did not agree with another study (23) , which proposed a hypoglutamatergic hypothesis for autism but did not explain the high incidence of seizures in autistic patients or the finding of elevated glutamate levels in the blood and cerebrospinal fluid.
Moreover, a meta-analysis of 12 studies concluded that glutamate might be a potential biomarker in ASD based on higher blood glutamate levels in patients than controls (24) . Another study, which measured essential and nonessential amino acids in autistic children, showed increases in the serum levels of glutamic acid, but with no significant differences between patients and controls (25) . Many studies have also investigated the underlying possible GABergic dysfunction, which may lead to deficient inhibition and increased excitation (26) .
In addition, there was no significant statistical difference in the serum levels of glutamate between patients receiving 1-2 mg of risperidone and those who had not taken it in the last six weeks before the test. The effects of antipsychotics were discussed in different studies on animals and humans. One study revealed that glutamate levels showed significant decreases in the associative striatum in patients after antipsychotic treatment but there was no significant difference between the patients and controls (27) .
In this study, no significant correlation was found between glutamate levels and the total scores or subscales of the CARS test that was used to assess the severity of ASD. Also, there was no correlation between the glutamate levels and the Vineland Social Maturity Scores. This reflected the fact that the glutamate levels were related to the diagnosis of autism rather than the severity. The severity of autism symptoms is influenced by many factors such as the type of behavioural and educational programmes including onset of intervention and the type of programmes that are offered and how soon they start after diagnosis (28) . They are also affected by biological factors, genetic load and psychosocial factors and there are definitely other undiscovered factors. This can explain the absence of significant direct correlation between the CARS scores and the glutamate level.
CONCLUSION
The significantly higher levels of serum glutamate observed in patients with ASD than the controls without ASD might reflect altered glutamatergic neurotransmission. This alteration can be directly involved in the pathophysiology of ASD. Larger sample studies, especially at younger ages, are needed to identify the serum glutamate levels in children presenting with ASD and to verify whether it can be used as a biomarker for early detection.
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